Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
about
High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in GabonCurrent ebola vaccinesEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentEbola virus vaccines: an overview of current approachesPre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutininEbola and Marburg virus vaccines.Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in MiceDevelopment of adenoviral vector-based mucosal vaccine against influenza.Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virusPrime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in miceDNA vaccines for biodefense.Mechanisms of immunity in post-exposure vaccination against Ebola virus infection.Filovirus vaccines.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineA Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola InfectionAdenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.Progress in filovirus vaccine development: evaluating the potential for clinical use.DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.Potential vaccines and post-exposure treatments for filovirus infections.Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus.Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Characterization of host immune responses in Ebola virus infections.Adenovirus-vectored Ebola vaccines.Fc receptors in antibody-dependent enhancement of viral infections.Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro.Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cellsAdenoviral type 35 and 26 vectors with a bidirectional expression cassette in the E1 region show an improved genetic stability profile and potent transgene-specific immune response.Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
P2860
Q21090030-1492000A-FB41-48F4-8BA3-988F9DF30677Q21534720-E33ED061-7086-4F51-B18F-6C2DAA59B4F9Q24597625-D7856C3B-A5A4-48FA-AECA-983738D56ACCQ26999232-51089CB1-01C5-49BC-846F-5B71CEE60484Q28731982-A47DA408-5AD5-429D-87C1-A63104D75D6FQ30234637-2F308512-29DC-4154-A8EA-9B883B0BCC69Q30375073-3F71154C-9500-426B-96E3-C1E721B306C0Q30396642-91CAC359-6D4F-4A09-A1A8-153FAF2AD04EQ33619065-F739019F-B604-411C-9EA6-E33784876F3FQ33981963-9660FDE5-C4BF-4750-BE24-1D2CA68309DFQ34000122-749958AD-2109-4553-AD84-82234378E23CQ34510430-69E521D0-7603-40ED-986D-D72E96320807Q34614260-518ACF8B-9989-4A02-9DD4-E8642CDE379BQ35192417-A528164E-ADAB-4633-982A-2610CD234430Q35558539-E57C446B-E927-4BE8-BB3F-838595B3E648Q35917496-FD19AE63-6005-422A-8414-D2D108DA7B30Q35917501-BEC4FE9D-087C-4D04-A835-2217668FD41CQ36043199-83126E37-BDE3-4A40-AF4F-C532BBA32F6FQ36100545-BBE1CA23-FD3B-4411-9782-93B725C19590Q36154869-283F63F7-E883-48BA-BCB8-04F3B9265E85Q36404178-FE1470E7-0494-419D-84E1-DFBE4A2B3F3BQ36433538-A3CF2E79-039C-43B5-B4E6-AC239BCA771CQ36580268-CCB749C0-E2DB-4042-B4B5-E9C0F609999EQ36759754-8C1BDEA1-D5F5-45F0-A6D0-0D98B6511B27Q36978876-F92E6EB9-1B4B-41A7-B115-B3397247890DQ36995725-DB91FCA7-6FAD-4584-B603-541AED74559DQ37627897-FB65B5DC-24A4-4122-91C8-9C50D23CD8DCQ38205274-A8B79186-836E-438A-8415-7320F9FDDBB9Q38569831-521AF7BD-1B60-4E85-B0E7-BE7137A256D3Q38615396-D840C108-12E3-4E1D-B2F6-150B5BF375D9Q38728732-BFF4BB53-58CD-4424-854A-39BF9E4FF54FQ39129671-475BFFA6-4C80-433D-B944-90A4F37F3B8DQ39413473-22EA9261-D624-4438-A67C-CD2635573B51Q40080155-41A66C66-C781-4007-9A98-FC68EC485530Q40153269-3A39B3FE-13EA-4E95-870A-C7C1B00B0D8CQ55010162-199D332F-9B6E-431F-BA37-77D57BDA20EC
P2860
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
@ast
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
@en
type
label
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
@ast
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
@en
prefLabel
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
@ast
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
@en
P2093
P2860
P921
P1433
P1476
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.
@en
P2093
James E Strong
Jason S Richardson
Kaylie N Tran
Maria A Croyle
Michel K Yao
P2860
P356
10.1371/JOURNAL.PONE.0005308
P407
P577
2009-04-23T00:00:00Z